Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hyblate Medical is a medical technology company focused on developing non-invasive high-intensity focused ultrasound (HIFU) solutions for the treatment of cardiac arrhythmias, specifically atrial fibrillation. The company's proprietary technology enables precise, contact-free ablation of cardiac tissue to achieve pulmonary vein isolation, which is the gold standard for treating atrial fibrillation. By utilizing ultrasound energy, Hyblate aims to offer a safer, faster, and more effective alternative to traditional catheter-based radiofrequency or cryoablation techniques. The system is designed to minimize the risks of collateral damage to surrounding tissues while improving procedural outcomes for patients.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hyblate Medical.